Correlation of serum level of HER-2 extracellular domain with HER-2 expression in tumor tissue of ;breast cancer patients and clinical significance
Yongpeng He,Lixian Li,Lin Yi,Chuang Ge,Weiqi Nian,Xiaodong Zheng
DOI: https://doi.org/10.3877/cma.j.issn.1674-0807.2016.01.004
2016-01-01
Abstract:Objective To investigate the correlation between serum level of HER-2 extracellular domain ( ECD) and HER-2 expression in tumor tissue of breast cancer patients and their relationship with clinicopathological parameters respectively .Methods Totally 93 breast cancer patients in Chongqing Cancer Institute from August 2013 to January 2014 were enrolled in this retrospective study .Those patients ’ serum and fresh tumor tissue samples were collected .Serum HER-2 ECD levels were measured by chemiluminescence immunoassay . HER-2 expression in tumor tissue was assessed by immunohistochemistry ( IHC) and fluorescence in situ hybridization ( FISH) .The results of serum HER-2 ECD levels and HER-2 expression in tumor tissue were compared , and their correlation with clinicopathological parameters was analyzed using χ2 test or Fisher’s exact probability test.t test was used to compare serum HER-2 ECD levels between HER-2 positive group and HER-2 negative group . The consistency of HER-2 level detected by serological method and histological method was analyzed by Kappa test.The correlation between tumor TNM staging and serum HER-2 ECD level was analyzed by Spearman rank test .Results There were 30 patients with HER-2 positive expression and 63 with HER-2 negative in 93 breast cancer patients .The serum HER-2 ECD level in HER-2 positive group was (22.18±22.38) ng/ml, significantly higher than (10.19±2.01) ng/ml in HER-2 negative group (t=-4.209, P<0.001).As for HER-2 detection, serological method showed a good consistency with histological method ( Kappa=0.519 , P<0.001 ) .The serum HER-2 ECD level in breast cancer patients was correlated with distal metastasis ( P=0.013 ) , tumor TNM staging ( r=0.213 ,P=0.042 ) , ER and PR status (χ2=6.206 , 11.853;P=0.013 , 0.001 ) , but not related to the patient ’ s age (χ2=0.607 , P=0.436 ) , tumor size ( P=0.109 ) , regional lymph node status ( P=0.106 ) , Ki67 and p53 expression (χ2=0.349 , 0.076;P=0.555 , 0.782 ) .The positive rate of HER-2 in tumor tissue in ER/PR negative patients was significantly higher than that in ER/PR positive patients (χ2 =15.368 , 24.733; all P <0.001 ) . Conclusions There is a significant correlation between serum HER-2 ECD level and HER-2 status in tumor tissue.The detection of serum HER-2 ECD level could be used as a supplement of histological detection to monitor continuous dynamic changes of HER-2 and provide objective references for clinical management of breast cancer .